Akers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers

by Vandana Singh, Benzinga Editor

February 23, 2021 1:25 PM | 1 min read | Make a Comment

Akers Biosciences Inc (NASDAQ: AKER) and its proposed merger partner MyMD Pharmaceuticals Inc have announced new data for MYMD-1 from the Eurofins Discovery Phenotypic Center of Excellence study.
MYMD-1 is being evaluated for autoimmune and age-related diseases.
The new findings indicate the potential of MYMD-1 to limit the fibrotic biology associated with idiopathic pulmonary fibrosis. MYMD-1 demonstrated inhibition of transforming growth factor-beta, a driver for fibrosis, and tumor necrosis factor, associated with inflammation.
MyMD plans to move forward in testing combinations of MyMD-1 with approved fibrosis drugs.
In November last year, Akers Biosciences and MyMD announced a merger agreement.
Price Action: AKER is down 9.8% at $3.12 in market trading hours on the last check Tuesday.

Posted In: Biotech M&A News Penny Stocks Health Care FDA General autoimmune diseases

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.